Recent developments include financial results reporting, significant financing secured, acquisitions, regulatory approvals, and strategic joint ventures expanding the company's cardiac electrophysiology technology portfolio.

• Catheter Precision reported Q3 2024 financial results highlighting revenue growth in LockeT sales and ongoing operational challenges [N1].
• The company secured $88 million in financing to support growth in aviation and medical sectors, despite a stock price decline [N2].
• Catheter Precision acquired Fly Flyte from Creatd, expanding its business scope [N3].
• LockeT wound closure device received approval in the UK, leading to a share price increase of over 65% [N4].
• The company launched a joint venture, KardioNav, with Chelak iECG to advance ventricular tachycardia ablation technology [N5].
• Catheter Precision addressed increased trading activity in its common stock [N6].
• The company secured its first order for the VIVO product from Sahlgrenska University Hospital in Sweden [N7].
• Catheter Precision received CE Mark approval for LockeT, expanding market opportunities in Europe [N8].

Catheter Precision has established a foundation with FDA clearance and CE Mark approvals for its core products, enabling market access in the U.S. and Europe. The company’s recent acquisitions and joint ventures expand its technology portfolio into promising areas like cardiac nerve stimulation and advanced ablation mapping, potentially broadening its product offerings. Successful commercialization of LockeT and VIVO, supported by long-term hospital contracts and distributor agreements, demonstrates market acceptance. The $88 million financing secured in 2026 provides capital to support growth initiatives. Continued clinical studies and regulatory clearances could enhance product indications and adoption.

The company faces significant financial challenges, including recurring net losses, negative cash flows, and liquidity constraints with a current ratio of 0.1 as of December 31, 2025. There is substantial doubt about its ability to continue as a going concern without additional financing. Market acceptance of products like VIVO has declined in some regions due to sales disruptions. The company’s reliance on raising capital introduces dilution risk and operational uncertainty. Regulatory approvals for new products and expanded indications remain uncertain. Competitive pressures from larger medical device companies and potential disruptions in supply chains or clinical trial execution pose risks to growth and profitability.

Catheter Precision's moat is based on its specialized medical technologies in cardiac electrophysiology, including FDA-cleared and CE Mark-approved products like the VIVO System and LockeT device. The company's intellectual property portfolio, including patents for LockeT and acquired technologies such as the CPNS System and ventricular ablation mapping innovations, supports product differentiation. Strategic partnerships and joint ventures, such as KardioNav with Chelak iECG, enhance its technological capabilities. However, the company operates in a competitive medical device market with larger players, and its moat depends on continued regulatory approvals, successful commercialization, and protection of intellectual property.

• Liquidity and Going Concern Risk: The company has low current assets relative to current liabilities, with a current ratio of 0.1 as of December 31, 2025, and has expressed substantial doubt about its ability to continue as a going concern without securing additional financing.
• Regulatory and Clinical Approval Risk: The company’s products require ongoing regulatory approvals and clearances, and clinical studies are necessary to expand indications. Failure to obtain or maintain these approvals could adversely affect commercialization.
• Competitive Risk: Operating in a competitive medical device market with larger, better-resourced competitors may limit market share and pricing power.
• Operational Execution Risk: The company’s growth depends on successful commercialization, sales execution, and integration of acquired technologies. Disruptions in sales leadership or clinical personnel could impact revenue.
• Financing and Dilution Risk: The company’s need for additional capital to fund operations and growth may result in dilution of existing shareholders and unfavorable financing terms.

• Catheter Precision, Inc. designs, manufactures, and sells innovative medical technologies focused on cardiac electrophysiology, primarily the VIVO System and the LockeT device.
• The VIVO System is a non-invasive 3D cardiac mapping system used to localize idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology procedures.
• The VIVO System has FDA clearance for marketing in the U.S. and CE Mark approval for the EU and certain other countries, with over 1,000 procedures performed in the U.S. and EU.
• LockeT is a suture retention device for wound healing, FDA registered as a Class I sterile product, with first sales recognized in May 2024 and CE Mark approval obtained in April 2025.
• LockeT has expanded market opportunities in Europe and the UK, with multiple distributor agreements signed in various countries.
• The company formed subsidiaries Cardionomix, Inc. and KardioNav, Inc. in 2025 to pursue development and commercialization of acquired assets and intellectual property related to cardiac treatment technologies.
• Cardionomix acquired the Cardiac Pulmonary Nerve Stimulation (CPNS) System assets in May 2025, a novel technology for late-stage treatment of acute decompensated heart failure, currently in development without regulatory approval.
• KardioNav is a joint venture with Chelak iECG, Inc. to develop advanced ventricular tachycardia ablation technology integrating VIVO mapping IP and Chelak's patents.
• The company completed acquisitions of PeriKard, LLC and Cardionomic assets in 2025, recognizing acquired in-process research and development expenses related to these assets.
• Revenues derive primarily from sales of VIVO System and LockeT device, with approximately 17-24% of sales from outside the U.S. in recent periods.
• LockeT sales increased due to sales efforts demonstrating procedural efficiency and cost-effectiveness, leading to long-term hospital contracts and repeat orders.
• VIVO System sales declined in the EU due to reduced sales efforts and changes in commercial leadership.
• The company has recurring net losses and negative cash flows from operations, with a net loss of approximately $17.2 million for fiscal year 2025 and basic EPS of -$15.9 per share.
• As of December 31, 2025, cash and cash equivalents were $88,000, current assets $390,000, current liabilities $3,907,000, resulting in a current ratio of 0.1 and a cash ratio of 1.3.
• The company has raised financing including a $1.5 million private placement in May 2025 and an $88 million financing secured in March 2026 to support growth in aviation and medical sectors.
• There is substantial doubt about the company's ability to continue as a going concern for one year after September 30, 2025, due to liquidity challenges and the need for additional financing.
• The company has royalty agreements related to LockeT sales, which reduce future profits from this product.
• The company faces risks including regulatory approvals, competitive pressures, financing availability, and operational execution challenges.
• The company has experienced increased trading activity and has addressed related stockholder communications.
• The company holds Level 3 trading debt securities measured at fair value with significant judgment involved in valuation.
• The company has material weaknesses in internal control over financial reporting and ongoing compliance requirements.
• The company’s business strategy focuses on becoming a leading medical device company in cardiac electrophysiology by developing products that improve ablation treatment outcomes.
• Recent developments include acquisition of Fly Flyte from Creatd, joint venture launch with Chelak iECG, and multiple regulatory approvals and orders for its products.